Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression

Last updated: March 24, 2025
Sponsor: University of Tartu
Overall Status: Active - Recruiting

Phase

N/A

Condition

Depression

Treatment

Therapeutic Intervention with Psychedelic Virtual Reality

Therapeutic Intervention with Non-Psychedelic Virtual Reality

Clinical Study ID

NCT06174285
DB-RCT-PSYRREAL
  • Ages 18-65
  • All Genders

Study Summary

Research has demonstrated that psychedelic compounds possess significant therapeutic potential for a variety of disorders, including depression. Despite these findings, the underlying mechanisms driving the therapeutic efficacy of psychedelics remain elusive. Furthermore, there exists a debate over the contribution of the subjective psychedelic experience to their therapeutic benefits. In this study, virtual reality (VR) is utilized as a tool to replicate the subjective experiences induced by psychedelics, aiming to explore their impact on depressive symptoms within a clinical sample.

The primary objective of this research is to examine the influence of psychedelic-like phenomenology, as simulated through VR, on depressive symptoms. The study is structured into two distinct arms: the experimental condition features 'Psyrreal,' a VR experience designed to emulate psychedelic effects and the control condition which includes 'Routine Realms,' an analogous VR experience devoid of psychedelic elements. A third waiting list condition may be included, dependent on the availability of sufficient participants and resources. Additionally, the study seeks to identify and analyze various potential mediators that might underpin the therapeutic outcomes observed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Persistent depressive symptoms observed during the initial screening and confirmedat baseline, as determined through a comprehensive psychiatric evaluation.

  • Provision of written informed consent by the participant.

  • Fluent in Estonian as a native language.

Exclusion

Exclusion Criteria:

  • Presence of significant impairments in vision, hearing, or balance.

  • Active suicidal ideation or current engagement in self-harm behaviors. Note:Individuals meeting this criterion will be directed to suitable crisis interventionservices.

  • Established diagnosis of bipolar disorder.

  • Manifestation of psychotic symptoms.

  • History of schizophrenia, either personally or within two generations of the familylineage.

  • Ongoing diagnosis of epilepsy, dementia, or any other neurological condition thatcould interfere with the effective utilization of virtual reality (VR) technology.

  • Susceptibility to motion sickness.

Study Design

Total Participants: 45
Treatment Group(s): 2
Primary Treatment: Therapeutic Intervention with Psychedelic Virtual Reality
Phase:
Study Start date:
November 06, 2023
Estimated Completion Date:
June 30, 2026

Connect with a study center

  • Confido Medical Centre

    Tallinn, Harjumaa 10138
    Estonia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.